133 related articles for article (PubMed ID: 32836195)
21. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of the serum IL-2R level and Ga-67 scan findings in making a differential diagnosis between sarcoidosis and non-Hodgkin's lymphoma.
Kita T; Watanabe S; Yano F; Hayashi K; Yamamoto M; Iwasaki Y; Kosuda S
Ann Nucl Med; 2007 Nov; 21(9):499-503. PubMed ID: 18030581
[TBL] [Abstract][Full Text] [Related]
23. Soluble interleukin-2 receptor in stage I-III melanoma.
Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
[TBL] [Abstract][Full Text] [Related]
24. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population.
Akiyama M; Sasaki T; Kaneko Y; Yasuoka H; Suzuki K; Yamaoka K; Takeuchi T
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):157-164. PubMed ID: 29465360
[TBL] [Abstract][Full Text] [Related]
25. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.
Salvarani C; Boiardi L; Macchioni P; Rossi F; Tartoni P; Casadei Maldini M; Mancini R; Beltrandi E; Portioli I
Ann Rheum Dis; 1995 Aug; 54(8):640-4. PubMed ID: 7677440
[TBL] [Abstract][Full Text] [Related]
26. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
[TBL] [Abstract][Full Text] [Related]
27. SACE and IL-2R as serum biomarkers for evaluation of multi-organ involvement and prognosis of sarcoidosis.
Zhou Y; Chen X; Zhao M; Lower EE; Baughman RP
Respir Res; 2023 Sep; 24(1):219. PubMed ID: 37679741
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
29. Correlation of spleen metabolism assessed by 18F-FDG PET with serum interleukin-2 receptor levels and other biomarkers in patients with untreated sarcoidosis.
Kalkanis A; Kalkanis D; Drougas D; Vavougios GD; Datseris I; Judson MA; Georgiou E
Nucl Med Commun; 2016 Mar; 37(3):273-7. PubMed ID: 26544095
[TBL] [Abstract][Full Text] [Related]
30. Soluble interleukin-2 receptor in sera of patients with pulmonary tuberculosis.
Takahashi S; Setoguchi Y; Nukiwa T; Kira S
Chest; 1991 Feb; 99(2):310-4. PubMed ID: 1989787
[TBL] [Abstract][Full Text] [Related]
31. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
32. Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity.
Bargagli E; Bianchi N; Margollicci M; Olivieri C; Luddi A; Coviello G; Grosso S; Rottoli P
Scand J Clin Lab Invest; 2008; 68(6):479-83. PubMed ID: 18609101
[TBL] [Abstract][Full Text] [Related]
33. Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study.
Mavropoulou E; Mechie NC; Knoop R; Petzold G; Ellenrieder V; Kunsch S; Pilavakis Y; Amanzada A
PLoS One; 2020; 15(5):e0233811. PubMed ID: 32470973
[TBL] [Abstract][Full Text] [Related]
34. [Changes in interleukin-2 receptor levels in active and inactive pulmonary sarcoidosis].
Strausz J; Joachim MQ; Rudolf F
Orv Hetil; 1991 Aug; 132(33):1803-6. PubMed ID: 1870863
[TBL] [Abstract][Full Text] [Related]
35. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K; Chizuka A
Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
[TBL] [Abstract][Full Text] [Related]
37. YKL-40, Soluble IL-2 Receptor, Angiotensin Converting Enzyme and C-Reactive Protein: Comparison of Markers of Sarcoidosis Activity.
Uysal P; Durmus S; Sozer V; Gelisgen R; Seyhan EC; Erdenen F; Simsek G; Uzun H
Biomolecules; 2018 Aug; 8(3):. PubMed ID: 30154391
[TBL] [Abstract][Full Text] [Related]
38. A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis.
Mostard RL; Van Kuijk SM; Verschakelen JA; van Kroonenburgh MJ; Nelemans PJ; Wijnen PA; Drent M
BMC Pulm Med; 2012 Sep; 12():57. PubMed ID: 22978780
[TBL] [Abstract][Full Text] [Related]
39. Elevated serum levels of soluble interleukin-2 receptors in active pulmonary sarcoidosis: relative specificity and association with hypercalcemia.
Lawrence EC; Berger MB; Brousseau KP; Rodriguez TM; Siegel SJ; Kurman CC; Nelson DL
Sarcoidosis; 1987 Sep; 4(2):87-93. PubMed ID: 2821601
[TBL] [Abstract][Full Text] [Related]
40. Correlation of serum tumor necrosis factor-alpha, interleukin-4 and soluble interleukin-2 receptor levels with radiologic and clinical manifestations in active pulmonary tuberculosis.
Kart L; Buyukoglan H; Tekin IO; Altin R; Senturk Z; Gulmez I; Demir R; Ozesmi M
Mediators Inflamm; 2003 Feb; 12(1):9-14. PubMed ID: 12745543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
